Introduction: The cell saver (CR) is an alternative to blood transfusion. It is used in surgical procedures that lose large blood concentrates, such as cardiac surgery under an extracorporeal circuit. Also CR is used in heart operations where they predict major blood loss, such as coronary and valve surgery, so we ask the research question; Is RC more effective in Company? Coronary with respect to the Company. Valve or vice versa? The objective of this study was to evaluate the efficacy of CR in reducing transfusion requirements in patients undergoing coronary and valvular surgery.

Methodology: Descriptive, longitudinal, prospective and observational study, where two cohorts of patients were established: Coronary group (CG), valvular group (GV), both groups were used CR. The study population is those who underwent coronary and valvular surgery, whose sample attends 30 patients, 15 for each group. Period of study 1-31 October 2014. Consent Informed to patient and Ethics Committee of our hospital. SPSS statistical package 18.

Results: Haemoglobin / Haematocrit: GC, 10.2gr/dl - 30.02%. GV, 9.8gr/dl - 28.16%. Autologous blood transfusion: GC, 95.1%. GV, 89.9%. p=0.37. Allogeneic blood transfusion: GC, 10.1% GV, 4.9%.

Conclusions: The cell saver is effective in the two surgical interventions studied, and there are no statistically significant differences. Therefore, its use as a measure to the reduction of allogeneic blood transfusion is recommended.